Advertisement

Review of Lifestyle and CAM for Miscellaneous Urologic Topics (Bladder Cancer, CP/CPPS, IC/PBS, Kidney Cancer): Part One

  • Mark A. Moyad
Chapter

Abstract

Multiple lifestyle changes have the ability to prevent bladder cancer (smoking cessation, reduce arsenic concentrations in water, increase cruciferous vegetable intake, etc.), and some dietary supplements, such as Lactobacillus casei Shirota, have the ability to reduce recurrence rates after superficial bladder cancer treatment from three randomized clinical trials. Chewing gum could be an option for patients post-cystectomy to improve bowel recovery time. Exercise could be a treatment option for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), and a variety of dietary supplements (quercetin complex, cernilton, etc.) are currently being utilized as part of the greater UPOINT conventional treatment paradigm. Interstitial cystitis/painful bladder syndrome (IC/PBS) has also being utilized CAM with some good efficacy and compliance. For example, elimination and restriction diets based on triggers as well as calcium glycerophosphate, glucosamine, chondroitin, hyaluronate, and quercetin complex may help patients with IC/PBS. And kidney cancer, compared to almost any other cancer, has some of the strongest associations with cardiovascular risk factors, especially obesity, smoking and hypertension, and a reduction in risk with exercise and dietary changes. Multiple urologic disease risks and even outcomes could be positively or negatively affected by CAM and should be objectively discussed with patients.

Keywords

Bladder Cancer Radical Cystectomy Kidney Cancer Pollen Extract Bladder Cancer Risk 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Grossman HB, Stenzl A, Moyad MA, Droller MJ. Bladder cancer: chemoprevention, complementary approaches and budgetary considerations. Scand J Urol Nephrol Suppl. 2008;218:213–33.PubMedCrossRefGoogle Scholar
  2. 2.
    Vilensky D, Lawrentschuk N, Hersey K, Fleshner NE. A smoking cessation program as a resource for bladder cancer patients. Can Urol Assoc J. 2012;6(5): E167–73.PubMedCrossRefGoogle Scholar
  3. 3.
    Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306:737–45.PubMedCrossRefGoogle Scholar
  4. 4.
    Rink M, Xylinas E, Babjuk M, Hansen J, Pycha A, Comploj E, et al. Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer. J Urol. 2012;188:2120–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Letasiova S, Medveova A, Sovcikova A, Dusinska M, Volkovova K, Mosolu C, et al. Bladder cancer, a review of environmental risk factors. Environ Health. 2012;11 Suppl 1:11.CrossRefGoogle Scholar
  6. 6.
    Flore MC, Baker TB. Should clinicians encourage smoking cessation for every patient who smokes? JAMA. 2013;309:1032–3.CrossRefGoogle Scholar
  7. 7.
    Stewart SB, Freedland SJ. Influence of obesity on the incidence and treatment of genitourinary malignancies. Urol Oncol. 2011;29:476–86.PubMedCrossRefGoogle Scholar
  8. 8.
    Chromecki TF, Cha EK, Fajkovic H, Rink M, Ehdaie B, Svatek RS, et al. Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. BJU Int. 2013;111:249–55.PubMedCrossRefGoogle Scholar
  9. 9.
    Liu B, Mao Q, Lin Y, Zhou F, Xie L. The association of cruciferous vegetables intake and risk of bladder cancer: a meta-analysis. World J Urol. 2013;31:127–33.PubMedCrossRefGoogle Scholar
  10. 10.
    Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Willett WC, Glovannucci EL. Fruit and vegetable intake and incidence of bladder cancer in a male prospective cohort. J Natl Cancer Inst. 1999;91:605–13.PubMedCrossRefGoogle Scholar
  11. 11.
    Lee JE, Mannisto S, Spiegelman D, Hunter DJ, Bernstein L, van den Brandt PA, et al. Intake of fruits, vegetables, and carotenoids and renal cell cancer risk: a pooled analysis of 13 prospective studies. Cancer Epidemiol Biomarkers Prev. 2009;18:1730–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Zhou J, Smith S, Giovannucci E, Michaud DS. Reexamination of total fluid intake and bladder cancer in the Health Professionals Follow-up Study Cohort. Am J Epidemiol. 2012;175:696–705.PubMedCrossRefGoogle Scholar
  13. 13.
    Donat SM, Bayuga S, Herr HW, Berwick M. Fluid intake and the risk of tumor recurrence in patients with superficial bladder cancer. J Urol. 2003;170: 1777–80.PubMedCrossRefGoogle Scholar
  14. 14.
    Curhan GC, Willett WC, Rimm EB, Spiegelman D, Stampfer MJ. Prospective study of beverage use and the risk of kidney stones. Am J Epidemiol. 1996;143:240–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Ferris J, Berbel O, Alonso-Lopez J, Garcia J, Ortega JA. Environmental non-occupational risk factors associated with bladder cancer. Actas Urol Esp. 2013 [Epub ahead of print].Google Scholar
  16. 16.
    Brinkman MT, Karagas MR, Zens MS, Schned AR, Reulen RC, Zeegers MP. Intake of alpha-linolenic acid and other fatty acids in relation to the risk of bladder cancer: results from the New Hampshire case–control study. Br J Nutr. 2011;106:1070–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Zhang XL, Geng J, Zhang XP, Peng B, Che JP, Yan Y, et al. Statin use and risk of bladder cancer: a meta-analysis. Cancer Causes Control. 2013;24:769–76.PubMedCrossRefGoogle Scholar
  18. 18.
    Silva RD, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Chade D, et al. Impact of statin use on oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy. J Urol. 2013;190:487–92.PubMedCrossRefGoogle Scholar
  19. 19.
    Defronzo RA, Mehta RJ, Schnure JJ. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. Hosp Pract. 1995;2013(41):132–47.Google Scholar
  20. 20.
    Campbell PT, Newton CC, Patel AV, Jacobs EJ, Gapstur SM. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care. 2012;35:1835–44.PubMedCrossRefGoogle Scholar
  21. 21.
    Xu X, Wu J, Mao Y, Zhu Y, Hu Z, Xu X, et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies. PLoS One. 2013;8:e58079.PubMedCrossRefGoogle Scholar
  22. 22.
    Schuhmacher-Wolz U, Dieter HH, Klein D, Schneider K. Oral exposure to inorganic arsenic: evaluation of its carcinogenic and non-carcinogenic effects. Crit Rev Toxicol. 2009;39:271–98.PubMedCrossRefGoogle Scholar
  23. 23.
    Zaghloul MS. Bladder cancer and schistosomiasis. J Egypt Natl Canc Inst. 2012;24:151–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Gaziano JM, Sesso HD, Christen WG, Bubes V, Smith JP, MacFadyen J, et al. Multivitamins in the prevention of cancer in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2012;308:1871–80.PubMedCrossRefGoogle Scholar
  25. 25.
    Sesso HD, Christen WG, Bubes V, Smith JP, MacFadyen J, Schvartz M, et al. Multivitamins in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2012;308:1751–60.PubMedCrossRefGoogle Scholar
  26. 26.
    Neuhouser ML, Wasserthell-Smoller S, Thomson C, Aragaki A, Anderson GL, Manson JE, et al. Multivitamin use and risk of cancer and cardiovascular disease in the Women’s Health Initiative cohorts. Arch Intern Med. 2009;169:294–304.PubMedCrossRefGoogle Scholar
  27. 27.
    Cole BF, Baron JA, Sandler RS, Polyp Prevention Study Group, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA. 2007;297:2351–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Figueriredo JC, Grau MV, Haile RW, et al. Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst. 2009;101:432–5.CrossRefGoogle Scholar
  29. 29.
    Collin SM, Metcalfe C, Refsum H, Lewis SJ, Zuccolo L, Smith GD, et al. Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case–control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2010;19:1632–42.PubMedCrossRefGoogle Scholar
  30. 30.
    Bailey RL, Mills JL, Yetley EA, Gahche JJ, Pfeiffer CM, Dwyer JT, et al. Unmetabolized serum folic acid and its relation to folic acid intake from diet and supplements in a nationally representative sample of adults aged > or =60 y in the United States. Am J Clin Nutr. 2010;92:383–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301:39–51.PubMedCrossRefGoogle Scholar
  32. 32.
    Duffield-Lillico AJ, Slate EH, Reid ME, Turnbull BW, Wilkins PA, Combs Jr GF, Nutritional Prevention of Cancer Study Group, et al. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst. 2003;95:1477–81.PubMedCrossRefGoogle Scholar
  33. 33.
    Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, Combs GF, et al. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med. 2007;147:217–23.PubMedCrossRefGoogle Scholar
  34. 34.
    Lawson KA, Wright ME, Subar A, Mouw T, Hollenbeck A, Schatzkin A, et al. Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J Natl Cancer Inst. 2007;99:754–64.PubMedCrossRefGoogle Scholar
  35. 35.
    Miller 3rd ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37–46.PubMedCrossRefGoogle Scholar
  36. 36.
    Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, B-vitamin Treatment Trialists’ Collaboration, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality. Meta-analysis of 8 randomized trials involving 37,485 individuals. Arch Intern Med. 2010;170:1622–31.PubMedCrossRefGoogle Scholar
  37. 37.
    Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2008;300:2123–33.PubMedCrossRefGoogle Scholar
  38. 38.
    Lamm DL, Riggs DR, Shriver JS, van Gilder PF, Rach JF, De Haven JI. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol. 1994;151: 21–6.PubMedGoogle Scholar
  39. 39.
    Nepple KG, Lightfoot AJ, Rosevear HM, O’Donnell MA, Lamm DL, Bladder Cancer Genitourinary Oncology Study Group. Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol. 2010;184:1915–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Moyad MA. Dr. Moyad’s no bogus science health advice. Ann Arbor, MI: Ann Arbor Media Group; 2010.Google Scholar
  41. 41.
    Morris MC, Tangney CC. A potential design flaw of randomized trials of vitamin supplements. JAMA. 2011;305:1348–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Tighe P, Ward M, McNulty H, Finnegan O, Dunne A, Strain J, et al. A dose-finding trial of the effect of long-term folic acid intervention: implications for food fortification policy. Am J Clin Nutr. 2011;93: 11–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Hercberg S, Galan P, Preziosi P, Bertrais S, Mennen L, Malvy D, et al. The SU.VI.MAX study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med. 2004;164:2335–42.PubMedCrossRefGoogle Scholar
  44. 44.
    Goossens ME, Buntinx F, Joniau S, Ackaert K, Ameye F, Billet I, et al. Designing the selenium and bladder cancer trial (SELEBLAT), a phase III randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium. BMC Urol. 2012;12:8.PubMedCrossRefGoogle Scholar
  45. 45.
    Moyad MA. Selenium and vitamin E supplements for prostate cancer: evidence or embellishment? Urology. 2002;59(4 Suppl 1):9–19.PubMedCrossRefGoogle Scholar
  46. 46.
    Giovannucci E, Chan AT. Role of vitamin and mineral supplementation and aspirin use in cancer survivors. J Clin Oncol. 2010;28:4081–5.PubMedCrossRefGoogle Scholar
  47. 47.
    Aso Y, Akazan H, BLP Study Group. Prophylactic effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer. Urol Int. 1992;49:125–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Aso Y, Akaza H, Kotake T, Tsukamoto T, Imai K, Naito S. Prevention effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. Eur Urol. 1995;27: 104–9.PubMedGoogle Scholar
  49. 49.
    Naito S, Koga H, Yamaguchi A, Fujimoto N, Hasui Y, Kuramoto H, Kyushu University Urological Oncology Group. Prevention of recurrence with epirubicin and Lactobacillus casei after transurethral resection of bladder cancer. J Urol. 2008;179:485–90.PubMedCrossRefGoogle Scholar
  50. 50.
    Dong H, Rowland I, Thomas LV, Yaqoob P. Immunomodulatory effects of a probiotc drink containing Lactobacillus casei Shirota in healthy older volunteers. Eur J Nutr. 2013; [Epub ahead of print].Google Scholar
  51. 51.
    Dong H, Rowland I, Yaqoob P. Comparative effects of six probiotic strains on immune function in vitro. Br J Nutr. 2012;108:459–70.PubMedCrossRefGoogle Scholar
  52. 52.
    Dong H, Rowland I, Tuohy KM, Thomas LV, Yaqoob P. Selective effects of Lactobacillus casei Shirota on T cell activation, natural killer cell activity and cytokine production. Clin Exp Immunol. 2010;161:378–88.PubMedGoogle Scholar
  53. 53.
    Ohashi Y, Nakai S, Tsukamoto T, Masumori N, Akaza H, Miyanaga N, et al. Habitual intake of lactic acid bacteria and risk reduction of bladder cancer. Urol Int. 2002;68:273–80.PubMedCrossRefGoogle Scholar
  54. 54.
    Larsson SC, Andersson SO, Johansson JE, Wolk A. Cultured milk, yogurt, and dairy intake in relation to bladder cancer risk in a prospective study of Swedish women and men. Am J Clin Nutr. 2008;88:1083–7.PubMedGoogle Scholar
  55. 55.
    Keszei AP, Schouten LJ, Goldbohm RA, van den Brandt PA. Dairy intake and the risk of bladder cancer in the Netherlands Cohort Study on Diet and Cancer. Am J Epidemiol. 2010;171:436–46.PubMedCrossRefGoogle Scholar
  56. 56.
    Li S, Liu Y, Peng Q, Xie L, Wang J, Qin X. Chewing gum reduces postoperative ileus following abdominal surgery: a meta-analysis of 17 randomized controlled trials. J Gastroenterol Hepatol. 2013;28:1122–32.PubMedCrossRefGoogle Scholar
  57. 57.
    Choi H, Kang SH, Yoon DK, Kang SG, Ko HY, du Moon G, et al. Chewing gum has a stimulatory effect on bowel motility in patients after open or robotic radical cystectomy for bladder cancer: a prospective randomized comparative study. Urology. 2011;77: 884–90.PubMedCrossRefGoogle Scholar
  58. 58.
    Kouba EJ, Wallen EM, Pruthi RS. Gum chewing stimulates bowel motility in patients undergoing radical cystectomy with urinary diversion. Urology. 2007;70:1053–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Pruthi RS, Nielsen M, Smith A, Nix J, Schultz H, Wallen EM. Fast track program in patients undergoing radical cystectomy: results in 362 consecutive patients. J Am Coll Surg. 2010;210:93–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Krieger JN, Nyberg Jr L, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999;282:236–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Shoskes DA, Nickel JC, Kattan MW. Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT. Urology. 2010;75:1249–53.PubMedCrossRefGoogle Scholar
  62. 62.
    Giubilei G, Mondaini N, Minervini A, Saieva C, Lapini A, Serni S, Bartoletti R, Carini M. Physical activity of men with chronic prostatitis/chronic pelvic pain syndrome not satisfied with conventional treatments-could it represent a valid option? The physical activity and male pelvic pain trial: a double-blind, randomized study. J Urol. 2007;177:159–65.PubMedCrossRefGoogle Scholar
  63. 63.
    Pool JL. Role of sympathetic nervous system in hypertension and benign prostatic hyperplasia. Br J Clin Pract Suppl. 1994;74:13–7.PubMedGoogle Scholar
  64. 64.
    McVary KT, Rademaker A, Lloyd GL, Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2005;174(4 Pt 1):1327–433.PubMedCrossRefGoogle Scholar
  65. 65.
    Esch T, Stefano GB. The neurobiology of stress management. Neuro Endocrinol Lett. 2010;31:19–39.PubMedGoogle Scholar
  66. 66.
    Murtezani A, Hundozi H, Orovcanec N, Sllamniku S, Osmani T. A comparison of high intensity aerobic exercise and passive modalities for the treatment of workers with chronic low back pain: a randomized, controlled trial. Eur J Phys Rehabil Med. 2011;47: 359–66.PubMedGoogle Scholar
  67. 67.
    Cohen JM, Fagin AP, Hariton E, Niska JR, Pierce MW, Kuriyama A, et al. Therapeutic intervention for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a systematic review and meta-analysis. PLoS One. 2012;7:e41941.PubMedCrossRefGoogle Scholar
  68. 68.
    Wagenlehner FM, Bschleipfer T, Pilatz A, Weidner W. Pollen extract for chronic prostatitis-chronic pelvic pain syndrome. Urol Clin N Am. 2011;38:285–92.CrossRefGoogle Scholar
  69. 69.
    Wagenlehner FME, Schneider H, Ludwig M, Schnitker J, Brahler E, Weidner W. A pollen extract (cernilton) in patients with inflammatory chronic-prostatitis-chronic pelvic pain syndrome: a multicentre, randomized, prospective, double-blind, placebo-controlled trial. Eur Urol. 2009;56:544–51.PubMedCrossRefGoogle Scholar
  70. 70.
    MacDonald R, Ishani A, Rutks I, Wilt TJ. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. BJU Int. 2000;85:836–41.PubMedCrossRefGoogle Scholar
  71. 71.
    Weng Z, Zhang B, Asadi S, Sismanopoulos N, Butcher A, Fu X, et al. Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in human. PLoS One. 2012;7:e33805.PubMedCrossRefGoogle Scholar
  72. 72.
    Shoskes DA, Zeitlin SI, Shahed A, Rajfer J. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology. 1999;54:960–3.PubMedCrossRefGoogle Scholar
  73. 73.
    Theoharides TC, O’Leary M. Painful bladder syndrome/interstitial cystitis: current concepts and role of nutraceuticals. Sem Prev Altern Med. 2006;14:2–6.Google Scholar
  74. 74.
    Hill JR, Isom-Batz G, Panagopoulos G, Zakariasen K, Kavaler E. Patient perceived outcomes of treatments used for interstitial cystitis. Urology. 2008;71:62–6.PubMedCrossRefGoogle Scholar
  75. 75.
    Bologna RA, Gomelsky A, Lukban JC, Tu LM, Holzberg AS, Whitmore KE. The efficacy of calcium glycerophosphate in the prevention of food-related flares in interstitial cystitis. Urology. 2001;57(6 Suppl 1):119–20.PubMedCrossRefGoogle Scholar
  76. 76.
    Bassaly R, Downes K, Hart S. Dietary consumption triggers in interstitial cystitis pain syndrome patients. Female Pelvic Med Reconstr Surg. 2011;17:36–9.PubMedCrossRefGoogle Scholar
  77. 77.
    Friedlander JI, Shorter B, Moldwin RM. Diet and its role in interstitial cystitis/bladder pain syndrome (IC/BPS) and comorbid conditions. BJU Int. 2012; 109:1584–91.PubMedCrossRefGoogle Scholar
  78. 78.
    Nguan C, Franciosi LG, Butterfield NN, Macleod BA, Jens M, Fenster HN. A prospective, double-blind, randomized cross-over study evaluating changes in urinary pH for relieving symptoms of interstitial cystitis. BJU Int. 2005;95:91–4.PubMedCrossRefGoogle Scholar
  79. 79.
    Thilagarajah R, Wltherow RO, Walker MM. Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial. BJU Int. 2001;87:207–12.PubMedCrossRefGoogle Scholar
  80. 80.
    O’Hare 3rd PG, Hoffman AR, Allen P, Gordon B, Salin L, Whitmore K. Interstitial cystitis patients’ use and rating of complementary and alternative medicine therapies. Int Urogynecol J. 2013;24:977–82.PubMedCrossRefGoogle Scholar
  81. 81.
    Theoharides TC, Sant GR. A pilot open label study of Cystoprotek in interstitial cystitis. Int J Immunopathol Pharmacol. 2005;18:183–8.PubMedGoogle Scholar
  82. 82.
    Theoharides TC, Kempuraj D, Vakall S, Sant GR. Treatment of refractory interstitial cystitis/painful bladder syndrome with CystoProtek-an oral multi-agent natural supplement. Can J Urol. 2008;15:4410–4.PubMedGoogle Scholar
  83. 83.
    Smith SD, Wheeler MA, Foster Jr HE, Weiss RM. Improvement in interstitial cystitis symptom scores during treatment with oral L-arginine. J Urol. 1997;158(3 Pt 1):703–8.PubMedGoogle Scholar
  84. 84.
    Korting GE, Smith SD, Wheeler MA, Weiss RM, Foster Jr HE. A randomized double-blind trial of oral L-arginine for treatment of interstitial cystitis. J Urol. 1999;161:558–65.PubMedCrossRefGoogle Scholar
  85. 85.
    Cartledge JJ, Davies AM, Eardley I. A randomized double-blind placebo-controlled crossover trial of the efficacy of L-arginine in the treatment of interstitial cystitis. BJU Int. 2000;85:421–6.PubMedCrossRefGoogle Scholar
  86. 86.
    Ehren I, Lundberg JO, Adolfsson J, Wiklund NP. Effects of L-arginine treatment on symptoms and bladder nitric oxide levels in patients with interstitial cystitis. Urology. 1998;52:1026–9.PubMedCrossRefGoogle Scholar
  87. 87.
    Katske F, Shoskes DA, Sender M, Poliakin R, Gagliano K, Rajfer J. Treatment of interstitial cystitis with a quercetin supplement. Tech Urol. 2001;7:44–6.PubMedGoogle Scholar
  88. 88.
    Fageril J, Fraser MO, de Groat WC, Chancellor MB, Flood HD, Smith D, et al. Intravesical capsaicin for the treatment of interstitial cystitis: a pilot study. Can J Urol. 1999;6:737–44.Google Scholar
  89. 89.
    French LM, Bhambore N. Interstitial cystitis/painful bladder syndrome. Am Fam Physician. 2011;83: 1175–81.PubMedGoogle Scholar
  90. 90.
    Lipworth L, Tarone RE, McLaughlin JK. Renal cell cancer among African Americans: an epidemiologic review. BMC Cancer. 2011;11:133.PubMedCrossRefGoogle Scholar
  91. 91.
    Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7:245–57.PubMedCrossRefGoogle Scholar
  92. 92.
    Moyad MA. Obesity, interrelated mechanisms, and exposures and kidney cancer. Semin Urol Oncol. 2001;19:270–9.PubMedGoogle Scholar
  93. 93.
    Khurana V, Caldito G, Ankem M. Statins might reduce risk of renal cell carcinoma in humans: case–control study of 500,000 veterans. Urology. 2008;71: 118–22.PubMedCrossRefGoogle Scholar
  94. 94.
    Behrens G, Leitzmann MF. The association between physical activity and renal cancer: systematic review and meta-analysis. Br J Cancer. 2013;108:798–811.PubMedCrossRefGoogle Scholar
  95. 95.
    Willett WC. Fruits, vegetables, and cancer prevention: turmoil in the produce section. J Natl Cancer Inst. 2010;102:1–2.CrossRefGoogle Scholar
  96. 96.
    Macleod LC, Hotaling JM, Wright JL, Davenport MT, Gore JL, Harper J, et al. Risk factors for renal cell carcinoma in the Vitamin and Lifestyle (VITAL) Study. J Urol. 2013; [epub ahead of print].Google Scholar
  97. 97.
    Lai GY, Park Y, Hartge P, Hollenbeck AR, Freedman ND. The association between self-reported diabetes and cancer incidence in the NIH-AARP Diet and Health Study. J Clin Endocrinol Metab. 2013;98:E497–502.PubMedCrossRefGoogle Scholar
  98. 98.
    Shu X, Lin J, Wood CG, Tannir NM, Wu X. Energy balance, polymorphisms in the mTOR pathway, and renal cell carcinoma risk. J Natl Cancer Inst. 2013;105:424–32.PubMedCrossRefGoogle Scholar
  99. 99.
    Beebe-Dimmer JL, Colt JS, Ruterbusch JJ, Keele GR, Purdue MP, Wacholder S, et al. Body mass index and renal cell cancer: the influence of race and sex. Epidemiology. 2012;23:821–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Mark A. Moyad
    • 1
  1. 1.Department of UrologyUniversity of Michigan Medical CenterAnn ArborUSA

Personalised recommendations